On July 22, 2009, eight public interest, consumer and public health organizations wrote to the United States Trade Representative (USTR), recommending the USTR and other federal agencies reduce secrecy and increase transparency in negotiations that involve global norms for knowledge governance.
The PAHO negotiations on the R&D resolution has produced a new draft, which radically guts the provision on transparency of pharmaceutical industry economics.
The US opposed this language:
“(j) to develop, with input from Member States, a possible standard for disclosure of economic data for drug registered for sale, including disclosures of the costs of R&D, the prices of products, and the annual revenues from the sale of products.”
The US agreed to this language:
Today the executive board of the Pan American Health Organization (PAHO) is considering a proposal to have more transparency of the economics of the pharmaceutical industry. (I have separately blogged about this on the Huffpo). Specifically, an amendment offered to a PAHO EB resolution on research, proposed the following:
The decision to restart the ACTA negotiations makes it important to understand the nature and consequence of proposed agreement. Following a complaint about transparency, this note focuses on damages and injunctions.
Using the U.S. Freedom of Information Act (FOIA), KEI has obtained the daily schedule of Ambassador Kirk, from March 20 to May 1, 2009. KEI has separately asked the USTR to routinely as a matter of transparency post this information on the USTR web page.